MX2023005501A - Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer. - Google Patents

Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer.

Info

Publication number
MX2023005501A
MX2023005501A MX2023005501A MX2023005501A MX2023005501A MX 2023005501 A MX2023005501 A MX 2023005501A MX 2023005501 A MX2023005501 A MX 2023005501A MX 2023005501 A MX2023005501 A MX 2023005501A MX 2023005501 A MX2023005501 A MX 2023005501A
Authority
MX
Mexico
Prior art keywords
inhibitors
cdk4
cancer
combinations
treatment
Prior art date
Application number
MX2023005501A
Other languages
English (en)
Inventor
James Shanahan
Peter Cornelius
Bradley J Carver
Original Assignee
Syndevrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndevrx Inc filed Critical Syndevrx Inc
Publication of MX2023005501A publication Critical patent/MX2023005501A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente divulgación está dirigida a combinaciones de inhibidores de MetAP2 e inhibidores de CDK4/6 para el tratamiento y la prevención del cáncer.
MX2023005501A 2020-11-11 2021-11-10 Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer. MX2023005501A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112217P 2020-11-11 2020-11-11
US202163166060P 2021-03-25 2021-03-25
PCT/US2021/058775 WO2022103834A1 (en) 2020-11-11 2021-11-10 Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2023005501A true MX2023005501A (es) 2023-07-27

Family

ID=78821168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005501A MX2023005501A (es) 2020-11-11 2021-11-10 Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer.

Country Status (8)

Country Link
US (1) US20230404963A1 (es)
EP (1) EP4243807A1 (es)
JP (1) JP2023550035A (es)
KR (1) KR20230117574A (es)
AU (1) AU2021378944A1 (es)
CA (1) CA3198173A1 (es)
MX (1) MX2023005501A (es)
WO (1) WO2022103834A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023100131A1 (en) * 2021-12-02 2023-06-08 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
WO2024036274A1 (en) * 2022-08-10 2024-02-15 Syndevrx, Inc. Metap2 inhibitors for the treatment of pulmonary fibrosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
WO2019070755A1 (en) * 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER

Also Published As

Publication number Publication date
US20230404963A1 (en) 2023-12-21
WO2022103834A1 (en) 2022-05-19
EP4243807A1 (en) 2023-09-20
AU2021378944A1 (en) 2023-06-15
CA3198173A1 (en) 2022-05-19
KR20230117574A (ko) 2023-08-08
JP2023550035A (ja) 2023-11-30

Similar Documents

Publication Publication Date Title
MX2021009563A (es) Combinacion farmaceutica que comprende tno155 y ribociclib.
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
MX2021011826A (es) Composiciones y combinaciones farmacéuticas que comprenden inhibidores del receptor de andrógenos y usos de estas.
MX2022004513A (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
MX2023005501A (es) Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer.
MX2021009562A (es) Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
NZ756754A (en) Combination therapy for the treatment or prevention of tumours
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MX2022001019A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MX2020013320A (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
MX2022000050A (es) Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
MX2021010916A (es) Inhibidores rad51.
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
MX2022012471A (es) Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
WO2021158635A8 (en) Anti-viral compositions and methods of use
MX2023008968A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
MX2023006542A (es) Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
MX2020014276A (es) Compuestos policiclicos como inhibidores de epoxido hidrolasa soluble.
MX2022013867A (es) Combinacion farmaceutica que comprende tno155 y nazartinib.
MX2022007457A (es) Metodos para tratar el coronavirus.
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.